Incyte (NASDAQ:INCY) Reaches New 1-Year High After Analyst Upgrade

Shares of Incyte Corporation (NASDAQ:INCY) hit a new 52-week high during trading on Wednesday after Morgan Stanley raised their price target on the stock from $92.00 to $94.00. Morgan Stanley currently has an equal weight rating on the stock. Incyte traded as high as $110.93 and last traded at $110.5540, with a volume of 523756 shares. The stock had previously closed at $106.66.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. increased their price target on shares of Incyte from $73.00 to $89.00 and gave the stock a “neutral” rating in a research report on Thursday, October 9th. Wall Street Zen upgraded Incyte from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Stifel Nicolaus set a $119.00 target price on Incyte in a research report on Monday. Piper Sandler boosted their price target on Incyte from $82.00 to $102.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Mizuho set a $121.00 price target on Incyte and gave the stock an “outperform” rating in a research report on Monday, December 8th. Eight equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $99.53.

Insiders Place Their Bets

In related news, EVP Steven H. Stein sold 20,105 shares of the stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the sale, the executive vice president owned 63,129 shares in the company, valued at approximately $6,471,353.79. This trade represents a 24.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of Incyte stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the sale, the executive vice president directly owned 66,132 shares in the company, valued at $7,213,017.24. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 99,174 shares of company stock worth $9,892,957 in the last three months. 17.80% of the stock is owned by company insiders.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Phase‑3 frontMIND success in first‑line high‑risk DLBCL — reported results drove earlier upside by substantially raising the approval and commercial potential for tafasitamab in a front‑line setting, a major positive for long‑term revenue prospects. Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL
• Positive Sentiment: Positive top‑line Phase‑III results for tafasitamab (DLBCL) — reinforces the clinical case and regulatory/commercial runway for the drug program. This is a direct catalyst for valuation re‑rating. Positive top-line results for Incyte’s tafasitamab in DLBCL
• Positive Sentiment: Bullish analyst commentary — Morgan Stanley projects strong price appreciation and Barclays initiated/maintained a buy, supporting investor interest and providing near‑term demand from institutional buyers. Morgan Stanley Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock Incyte (INCY) Gets a Buy from Barclays
• Neutral Sentiment: INCB123667 completed Phase‑1 (early safety) — an important de‑risking step but still early; positive for pipeline breadth but limited immediate revenue impact. Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
• Neutral Sentiment: Broader analyst coverage and stock‑screen features — additional attention (The Globe and Mail, Zacks) can boost liquidity/interest but does not by itself change fundamentals. Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Incyte (INCY) Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Neutral Sentiment: Patient/therapy coverage (chronic GVHD story) highlights real‑world benefit of treatments in Incyte’s therapeutic areas, which supports long‑term product adoption but is not an immediate earnings catalyst. How a Chronic GVHD Treatment Is Helping Patients Stay One Step Ahead
• Negative Sentiment: Insider selling by EVP Mohamed Khairie Issa — sale of ~10,856 shares (filed with the SEC) may be read as executive profit‑taking and can weigh on sentiment, especially on a day with mixed newsflow. SEC Filing — Insider Sale
• Negative Sentiment: Competitor/market developments: Monjuvi (tafasitamab/combination data) being added to chemo regimens strengthens class evidence but could also shift competitive dynamics and reimbursement conversations — a mixed-to-negative near‑term read depending on commercialization details. Monjuvi Added to Standard Chemotherapy Improves Outcomes in Lymphoma

Hedge Funds Weigh In On Incyte

Hedge funds have recently modified their holdings of the stock. Bank of Nova Scotia grew its stake in Incyte by 0.7% during the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock valued at $1,160,000 after acquiring an additional 124 shares in the last quarter. MAI Capital Management grew its position in shares of Incyte by 19.9% during the second quarter. MAI Capital Management now owns 754 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 125 shares in the last quarter. Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Incyte by 0.9% in the third quarter. Atlantic Edge Private Wealth Management LLC now owns 14,556 shares of the biopharmaceutical company’s stock worth $1,235,000 after purchasing an additional 125 shares during the last quarter. Perbak Capital Partners LLP lifted its position in shares of Incyte by 2.5% in the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock worth $449,000 after buying an additional 129 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Incyte by 1.7% during the second quarter. Assenagon Asset Management S.A. now owns 8,993 shares of the biopharmaceutical company’s stock valued at $612,000 after buying an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Incyte Stock Performance

The company has a market capitalization of $20.79 billion, a P/E ratio of 17.74, a price-to-earnings-growth ratio of 0.67 and a beta of 0.82. The business has a 50 day moving average of $101.84 and a 200 day moving average of $87.82. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.26 billion. During the same period in the prior year, the firm earned $1.07 EPS. The company’s revenue for the quarter was up 20.0% on a year-over-year basis. On average, sell-side analysts predict that Incyte Corporation will post 4.86 earnings per share for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.